ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Targeting CEBPA/ALOX15B attenuates postmenopausal osteoporosis by inhibiting ferroptosis through the AMPK/mTOR signaling pathway.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage metabolic reprogramming via HIF-1α-glycolysis drives osteoblast ferroptosis and bone loss through an IL-6-STAT3-dependent redox axis.Redox report : communications in free radical research · 2026Article
- The estrogen-ferroptosis axis in postmenopausal osteoporosis, osteoarthritis, and intervertebral disc degeneration: shared mechanisms and emerging evidence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePostmenopausal osteoporosis (PMOP) is characterized by bone loss attributed to estrogen deficiency; however, the involvement of ferroptosis in its pathogenesis has yet to be fully elucidated. The objective of this study was to explore the regulatory mechanism of the CEBPA/ALOX15B axis in PMOP, with a focus on modulating ferroptosis.
methodsFour gene expression datasets (GSE56116, GSE56814, GSE56815, GSE230665) were analyzed to identify differentially expressed genes (DEGs) and ferroptosis-related genes (FRGs) in PMOP. In vitro experimental approaches, including cell viability, apoptosis, ferroptosis marker detection, and osteogenic differentiation assays, were conducted in hFOB 1.19 cells with ALOX15B/CEBPA knockdown/overexpression. The AMPK/mTOR pathway was validated using Western blot and pharmacological inhibitors. In vivo, ALOX15B knockout mice were subjected to ovariectomy (OVX) to establish a PMOP model, and bone mineral density (BMD), micro-CT, and histopathological analyses were performed.
resultsALOX15B was significantly upregulated in PMOP patients, negatively correlating with estrogen levels. ALOX15B knockdown in hFOB 1.19 cells suppressed ferroptosis (reduced Fe²⁺, MDA, ROS, and PTGS2; increased GSH/GSSG and GPX4) and promoted osteoblast differentiation (elevated ALP, RUNX2, OCN). Mechanistically, CEBPA directly bound to the ALOX15B promoter to transcriptionally activate it. CEBPA/ALOX15B regulated ferroptosis and osteogenesis via the AMPK/mTOR axis. In OVX mice, ALOX15B knockout ameliorated bone loss (increased BMD, BV/TV, Tb.Th; reduced Tb.Sp) and ferroptosis (decreased iron deposition, 4-HNE; increased GPX4).
conclusionThe CEBPA/ALOX15B axis promotes osteoblast ferroptosis in PMOP by inhibiting the AMPK/mTOR pathway, providing a novel therapeutic target for PMOP treatment.
Indexed as
Identifiers
41843143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.